source
- BMS to consolidate R&D under single leader as chief research officer exitsBristol Myers Squibb announced a reorganization of its research and development unit, merging early research and discovery with drug development under a single leader. Chief Research Officer Rober…
- PepGen stock surges as DM1 oligonucleotide PGN-EDODM1 shows record splicing correction in Phase 2PepGen reported that its experimental oligonucleotide PGN-EDODM1 achieved a mean splicing correction of 46.5% at week 13 in a Phase 2 trial for myotonic dystrophy type 1 (DM1). This performance exc…